The mode of action of THC in the human body has been the subject of numerous studies in recent years. THC primarily activates specific binding sites in the body’s cells, the so-called cannabinoid receptors. Two of these have undergone extensive research, the cannabinoid 1 receptor (CB1 receptor), whose activation by THC triggers the well-known psychoactive effects and also certain therapeutic effects, as well as the cannabinoid 2 receptor (CB2 receptor).

The therapeutic effect of semi-synthetically manufactured and natural THC.

So far, clinical studies have documented efficacy for:

  • Nausea and vomiting, especially in the case of patients undergoing chemotherapy
  • Cachexia and loss of appetite among HIV and cancer patients
  • Spasticity and neuropathic pain for multiple sclerosis sufferers
  • Spastic bladder dysfunction for multiple sclerosis sufferers or those who are paralysed
  • Tourette’s syndrome
  • Neuropathic pain among HIV/Aids sufferers
  • Glaucoma
  • Pain associated with rheumatoid arthritis

The therapeutic effect of fully synthetically manufactured THC

So far, non-randomised studies, descriptive studies or experiential reports have documented efficacy for:

  • Alzheimer’s disease
  • Parkinson’s disease
  • Growth inhibition in the case of glioblastoma
  • Morbus Crohn and other inflammatory bowel diseases
  • Chronic pain
  • Neuropathic pain
  • Epilepsy

Durch die weitere Nutzung der Seite stimmen Sie der Verwendung von Cookies zu. Weitere Informationen

Die Cookie-Einstellungen auf dieser Website sind auf "Cookies zulassen" eingestellt, um das beste Surferlebnis zu ermöglichen. Wenn du diese Website ohne Änderung der Cookie-Einstellungen verwendest oder auf "Akzeptieren" klickst, erklärst du sich damit einverstanden.

Schließen